A Study of Encorafenib Plus Cetuximab With or Without Chemotherapy in People With Previously Untreated Metastatic Colorectal Cancer
Study Details
Study Description
Brief Summary
The purpose of this study is to evaluate two study medicines (encorafenib plus cetuximab) taken alone or together with standard chemotherapy for the potential treatment of colorectal cancer that:
-
has spread to other parts of the body (metastatic);
-
has a certain type of abnormal gene called "BRAF"; and
-
has not received prior treatment.
Participants in this study will receive one of the following study treatments:
-
Encorafenib plus cetuximab: These participants will receive encorafenib by mouth at home every day and cetuximab once every two weeks by intravenous (IV) infusion (an injection into the vein) at the study clinic.
-
Encorafenib plus cetuximab with chemotherapy: These participants will receive encorafenib and cetuximab in the way described in the bullet above. Additionally, they will receive standard chemotherapy by IV infusion and oral treatment at home.
-
Chemotherapy alone: These participants will receive chemotherapy, the standard treatment for this condition, by IV infusion at the study clinics and oral treatment at home.
The study team will monitor how each participant responds to the study treatment for up to about 3 years.
Condition or Disease | Intervention/Treatment | Phase |
---|---|---|
Phase 3 |
Detailed Description
The purpose of the study is to evaluate whether encorafenib plus cetuximab (EC), alone or in combination with chemotherapy, can improve clinical outcomes relative to current standard of-care chemotherapy in participants with previously untreated BRAF V600E-mutant mCRC. Since encorafenib has not previously been combined with chemotherapy, the tolerability and PK of EC in combination with mFOLFOX6 and in combination with FOLFIRI will be evaluated in separate cohorts in the safety lead-in portion of the trial in order to identify which chemotherapy combination is to be used in the Phase 3 portion of the study.
Study Design
Arms and Interventions
Arm | Intervention/Treatment |
---|---|
Experimental: Safety Lead-in Cohort 1 Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks Irinotecan 180 mg/m2 (90-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks |
Drug: Encorafenib
75 mg capsules
Other Names:
Drug: Cetuximab
Injection for intravenous use 100 mg/vial, 200 mg/vial, or 500 mg/vial
Other Names:
Drug: Irinotecan
Solution for intravenous infusion 40 mg/vial, 100 mg/vial, or 300 mg/vial
Other Names:
Drug: Leucovorin
Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial
Other Names:
Drug: 5-FU
Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial
Other Names:
|
Experimental: Safety Lead-in Cohort 2 Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120 minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks |
Drug: Encorafenib
75 mg capsules
Other Names:
Drug: Cetuximab
Injection for intravenous use 100 mg/vial, 200 mg/vial, or 500 mg/vial
Other Names:
Drug: Oxaliplatin
Powder for solution for intravenous use 50 mg/vial, 100 mg/vial, or 200 mg/vial
Other Names:
Drug: Leucovorin
Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial
Other Names:
Drug: 5-FU
Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial
Other Names:
|
Experimental: Phase 3 Arm A Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120-minute IV infusion) every two weeks |
Drug: Encorafenib
75 mg capsules
Other Names:
Drug: Cetuximab
Injection for intravenous use 100 mg/vial, 200 mg/vial, or 500 mg/vial
Other Names:
|
Experimental: Phase 3 Arm B Encorafenib 300 mg orally once daily Cetuximab 500 mg/m2 (120 minute IV infusion) every two weeks Oxaliplatin 85 mg/m2 (120-minute IV infusion) every two weeks Leucovorin 400 mg/m2 (120-minute IV infusion) every two weeks 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours every two weeks |
Drug: Encorafenib
75 mg capsules
Other Names:
Drug: Cetuximab
Injection for intravenous use 100 mg/vial, 200 mg/vial, or 500 mg/vial
Other Names:
Drug: Oxaliplatin
Powder for solution for intravenous use 50 mg/vial, 100 mg/vial, or 200 mg/vial
Other Names:
Drug: Irinotecan
Solution for intravenous infusion 40 mg/vial, 100 mg/vial, or 300 mg/vial
Other Names:
Drug: Leucovorin
Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial
Other Names:
Drug: 5-FU
Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial
Other Names:
|
Active Comparator: Phase 3 Arm C Every two weeks: Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 400 mg/m2 IV bolus, then 5-FU 2400 mg/m2 continuous IV infusion over 46-48 hours Bevacizumab (optional; given per prescribing instructions) -OR- Every two weeks: Irinotecan 165 mg/m2 (90-minute IV infusion) Oxaliplatin 85 mg/m2 (120-minute IV infusion) Leucovorin 400 mg/m2 (120-minute IV infusion) 5-FU 2400 or 3200 mg/m2 continuous IV infusion over 46 48 hours Bevacizumab (optional; given per prescribing instructions) -OR- Oxaliplatin 130 mg/m2 (120-minute IV infusion) every 3 weeks Capecitabine 1000 mg/m2 oral tablet twice daily on Days 1-14 Bevacizumab (optional; given per prescribing instructions) |
Drug: Oxaliplatin
Powder for solution for intravenous use 50 mg/vial, 100 mg/vial, or 200 mg/vial
Other Names:
Drug: Irinotecan
Solution for intravenous infusion 40 mg/vial, 100 mg/vial, or 300 mg/vial
Other Names:
Drug: Leucovorin
Injection 50 mg/vial, 100 mg/vial, 200 mg/vial, or 350 mg/vial
Other Names:
Drug: 5-FU
Injection for intravenous use 250 mg/vial, 500 mg/vial, or 1000 mg/vial
Other Names:
Drug: Capecitabine
150 mg or 500 mg Tablet
Other Names:
Drug: Bevacizumab
Optional Injection for intravenous use 100 mg/vial or 400 mg/vial
Other Names:
|
Outcome Measures
Primary Outcome Measures
- Safety Lead-in Study: Incidence of Dose Limiting Toxicities (DLTs) [After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months]
Incidence of dose limiting toxicity defined as any adverse event (AE) or abnormal laboratory value assessed as unrelated to disease, disease progression, intercurrent illness or concomitant medications/therapies occurring during the first 28 days of treatment
- Phase 3: Progression free survival, by blinded independent review [Duration of Phase 3, approximately 34 months]
Progression free survival, defined as the time from the date of randomization to the earliest documented disease progression or death due to any cause: encorafenib and cetuximab + mFOLFOX6 (Arm B) vs the Control Arm (Arm C)
Secondary Outcome Measures
- Safety Lead-in: Incidence of adverse events [After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months]
An adverse event is any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship as assessed by CTCAE 4.03
- Safety Lead-in: Incidence of abnormal clinical laboratory parameters, abnormal vital signs and abnormal electrocardiograms [After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months]
Changes in clinical laboratory parameters, vital signs and electrocardiograms determined clinically significant at the investigator's discretion.
- Safety Lead-in: Incidence of dose interruptions, dose modifications and discontinuations due to adverse events [After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months]
- Safety Lead-in: Overall response rate by investigator [After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months]
Overall response rate, defined as the proportion of participants who have achieved a confirmed best overall response per RECIST v1.1: encorafenib and cetuximab + mFOLFOX6 or FOLFIRI
- Safety Lead-in: Duration of response by Investigator [After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months]
Duration of response, defined as the time from the date of first radiographic evidence of response to the earliest documented disease progression per RECIST v1.1, or death due to any cause: encorafenib and cetuximab + mFOLFOX6 or FOLFIRI
- Safety Lead-in:Progression free survival by Investigator [After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months]
Progression free survival, defined as the time from the first dose to the earliest documented disease progression per RECIST v1.1, or death due to any cause: encorafenib and cetuximab + mFOLFOX6 or FOLFIRI
- Safety Lead-in: Time to response by Investigator [After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months]
Time to response, defined as the time from first dose to first radiographic evidence of response per RECIST v1.1: encorafenib and cetuximab + mFOLFOX6 or FOLFIRI
- Safety Lead-in: Overall survival [After 30 evaluable patients in each cohort complete 1 cycle (up to 28 days), approximately 12 months]
Overall survival defined as the time from the first dose to death due to any cause: encorafenib and cetuximab + mFOLFOX6 or FOLFIRI
- Phase 3: Overall survival and Progression free survival by blinded independent review [Duration of Phase 3, approximately 34 months]
Overall survival, defined as the time from the date of randomization to death due to any cause: encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encorafenib + cetuximab +mFOLFOX6 (Arm B) and progression free survival, defined as the time from the date of randomization to the earliest documented disease progression or death due to any cause: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C)
- Phase 3: Overall response rate by blinded independent review and by Investigator [Duration of Phase 3, approximately 34 months]
Overall response rate, defined as the proportion of participants who have achieved a confirmed best overall response per RECIST v1.1: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encorafenib + cetuximab +mFOLFOX6 (Arm B)
- Phase 3: Duration of response by blinded independent review and by Investigator [Duration of Phase 3, approximately 34 months]
Duration of response, defined as the time from the date of first radiographic evidence of response to the earliest documented disease progression per RECIST v1.1, or death due to any cause: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encorafenib + cetuximab +mFOLFOX6 (Arm B)
- Phase 3: Time to response by blinded independent review and by Investigator [Duration of Phase 3, approximately 34 months]
Time to response, defined as the time from first dose to first radiographic evidence of response per RECIST v1.1: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encorafenib + cetuximab +mFOLFOX6 (Arm B)
- Phase 3: Progression free survival by Investigator [Duration of Phase 3, approximately 34 months]
Progression free survival, defined as the time from the first dose to the earliest documented disease progression per RECIST v1.1, or death due to any cause:: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encorafenib + cetuximab +mFOLFOX6 (Arm B)
- Phase 3: Progression free survival 2 by Investigator [Duration of Phase 3, approximately 34 months]
Progression free survival 2, defined as the time from the date of randomization to the second objective disease progression per RECIST v1.1, or death from any cause, whichever occurs first: encorafenib + cetuximab (Arm A) vs Control Arm (Arm C) and encorafenib + cetuximab +mFOLFOX6 (Arm B) vs Control Arm (Arm C) and encorafenib + cetuximab (Arm A) vs encorafenib + cetuximab +mFOLFOX6
- Phase 3: Incidence of adverse events [Duration of Phase 3, approximately 34 months]
An adverse event was any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship: encorafenib + cetuximab (Arm A) and encorafenib + cetuximab +mFOLFOX6 (Arm B)
- Phase 3: Incidence of abnormal clinical laboratory parameters, abnormal vital signs and abnormal electrocardiograms [Duration of Phase 3, approximately 34 months]
Changes in clinical laboratory parameters, vital signs and electrocardiograms determined clinically significant at the investigator's discretion: encorafenib + cetuximab (Arm A) and encorafenib + cetuximab +mFOLFOX6 (Arm B)
- Phase 3: Change from Baseline in the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (EORTC QLQ-C30) [Duration of Phase 3, approximately 34 months]
EORTC QLQ-C30: included functional scales (physical, role, cognitive, emotional, and social), global health status, symptom scales (fatigue, pain, nausea/vomiting) and single items (dyspnoea, appetite loss, insomnia, constipation/diarrhea and financial difficulties). Most questions used 4 point scale (1 'Not at all' to 4 'Very much'; 2 questions used 7-point scale (1 'very poor' to 7 'Excellent'). Scores averaged, transformed to 0-100 scale; higher score=better level of functioning or greater degree of symptoms.
- Phase 3: Change from Baseline in the EuroQol-5D-5L (EQ-5D-5L) Questionnaire [Duration of Phase 3, approximately 34 months]
The EQ-5D-5L is a standardized measure of health utility that provides a single index value for the participant's health status. It is frequently used for economic evaluations of health care and has been shown to be a valid and reliable instrument, and comprises a short descriptive system questionnaire and a visual analogue scale (EQ VAS) that are cognitively undemanding, taking about 2 minutes to complete
- Phase 3: Change from Baseline in the Patient Global Impression of Severity (PGIS) [Duration of Phase 3, approximately 34 months]
The PGIS is a single-item questionnaire designed to assess participant's overall impression of disease severity at a given point in time.
- Phase 3: Change from Baseline in the Patient Global Impression of Change (PGIC) questionnaires [Duration of Phase 3, approximately 34 months]
The PGIC is a single-item questionnaire designed to assess the participant's overall sense of whether there has been a change in symptoms or quality of life since starting treatment.
- Phase 3: Confirm the MSI-status in tumor tissue [Once, pre-treatment]
Summarize MSI-status as determined by retrospective central testing of baseline tumor tissue
- Phase 3: Determine the correlation between cfDNA genetic alterations and clinical outcome [Predose on Cycle 1 Day 1, Cycle 1 Day 15, Cycle 2 Day 15 and Cycle 7 Day 1. Each cycle is 28 days for all treatments except for oxaliplatin/capecitabine treatment which is 21 days]
BRAF V600E variant allele fraction (VAF) and/or overall mean VAF from cfDNA analysis of plasma samples collected at baseline and on treatment
- Safety Lead-in: Maximum plasma concentration of encorafenib, LHY746, irinotecan and SN-38 [Cycle 1 Day 1 and Day 15: predose, and 0.75, 1.5, 2.5, 3.5, 5.5 and 7.5 hours after dosing, Cycle 1 Day 3 and Day 17:predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days]
- Safety Lead-in: Area under the plasma concentration time curve of encorafenib, LHY746, irinotecan and SN-38 [Cycle 1 Day 1 and Day 15: predose, and 0.75, 1.5, 2.5, 3.5, 5.5 and 7.5 hours after dosing, Cycle 1 Day 3 and Day 17:predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days. Each cycle is 28 days]
- Safety Lead-in: Time to maximim plasma concentration time curve of encorafenib, LHY746, irinotecan and SN-38 [Cycle 1 Day 1 and Day 15: predose, and 0.75, 1.5, 2.5, 3.5, 5.5 and 7.5 hours after dosing, Cycle 1 Day 3 and Day 17:predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days]
- Safety Lead-in: Maximum plasma concentration of encorafenib, LHY746 and oxaliplatin [Cycle 1 Day 1 and Day 15: predose, and 1, 2, 3, 4, 6 and 8 hours after dosing, Cycle 1 Day 3 and Day 17: predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days]
- Safety Lead-in: Area under the plasma concentration time curve of encorafenib, LHY746 and oxaliplatin [Cycle 1 Day 1 and Day 15: predose, and 1, 2, 3, 4, 6 and 8 hours after dosing, Cycle 1 Day 3 and Day 17: predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days]
- Safety Lead-in: Clearance of irinotecan, SN-38 and oxaliplatin [Cycle 1 Day 1 and Day 15: predose, and 0.75, 1.5, 2.5, 3.5, 5.5 and 7.5 hours after dosing, Cycle 1 Day 3 and Day 17:predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days]
Changes in exposures of irinotecan and its metabolite (SN-38) on Cycle 1 Day 15 compared to Cycle 1 Day 1 in Cohort 1 (encorafenib and cetuximab + FOLFIRI) Changes in exposures of oxaliplatin on Cycle 1 Day 15 compared to Cycle 1 Day 1 in Cohort 2 (encorafenib and cetuximab + mFOLFOX6)
- Safety Lead-in: Time to maximim plasma concentration time curve of encorafenib, LHY746 and oxaliplatin [Cycle 1 Day 1 and Day 15: predose, and 1, 2, 3, 4, 6 and 8 hours after dosing, Cycle 1 Day 3 and Day 17: predose and Cycle 2 through Cycle 6: Day 1 predose. Each cycle is 28 days]
- Phase 3: Trough concentrations of encorafenib and its metabolite LHY746 [Predose on Cycle 1 through Cycle 6. Each cycle is 28 days]
Trough plasma concentrations in all patients in Arm A and Arm B
Eligibility Criteria
Criteria
Inclusion Criteria:
-
Safety Lead-In = Male/female ≥ 18 years old
-
Phase 3: Male/female ≥ 16 years old (where permitted locally)
-
Histologically or cytologically confirmed Stage IV CRC that contains BRAF V600E mutation
-
Prior systemic treatment in metastatic setting
-
SLI: 0-1 regimens
-
Phase 3: None
-
Prior adjuvant or neoadjuvant therapy considered metastatic treatment if relapse/metastasis < 6 month from end of adj/neoadjuvant treatment
-
Measurable disease (Phase 3)/ Measurable or evaluable disease (Safety Lead-in)
-
ECOG PS 0-1
-
Adequate organ function
Exclusion Criteria:
-
Tumors that are locally confirmed or unknown MSI-H or dMMR unless participant is ineligible to receive immune checkpoint inhibitors due to a pre-existing medical condition
-
Active bacterial or viral infections in 2 weeks prior to starting dosing
-
Symptomatic brain metastases
Contacts and Locations
Locations
Site | City | State | Country | Postal Code | |
---|---|---|---|---|---|
1 | Mayo Clinic - Phoenix Oncology Pharmacy | Phoenix | Arizona | United States | 85054 |
2 | Mayo Clinic Hospital | Phoenix | Arizona | United States | 85054 |
3 | Mayo Clinic in Arizona - Scottsdale | Scottsdale | Arizona | United States | 85259 |
4 | Tower Hematology Oncology Medical Group (THO) | Beverly Hills | California | United States | 90211 |
5 | Keck Hospital of USC | Los Angeles | California | United States | 90033 |
6 | LAC & USC Medical Center | Los Angeles | California | United States | 90033 |
7 | USC / Norris Comprehensive Cancer Center | Los Angeles | California | United States | 90033 |
8 | USC/Norris Comprehensive Cancer Center / Investigational Drug Services | Los Angeles | California | United States | 90033 |
9 | USC/Norris Comprehensive Cancer Center | Los Angeles | California | United States | 90033 |
10 | Cedars- Sinai Medical Center | Los Angeles | California | United States | 90048 |
11 | Cedars-Sinai Medical Center, Samuel Oschin Comprehensive Cancer Institute | Los Angeles | California | United States | 90048 |
12 | Cedars-Sinai Medical Center | Los Angeles | California | United States | 90048 |
13 | Keck Hospital of USC Pasadena | Pasadena | California | United States | 91105 |
14 | Torrance Memorial Medical Center (TMMC) | Torrance | California | United States | 90505 |
15 | Georgetown University Medical Center | Washington | District of Columbia | United States | 20007 |
16 | Medstar Georgetown University Hospital | Washington | District of Columbia | United States | 20007 |
17 | Mount Sinai Comprehensive Cancer Center, Aventura | Aventura | Florida | United States | 33180 |
18 | Sylvester Comprehensive Cancer Center- The Lennar Foundation Medical Center | Coral Gables | Florida | United States | 33146 |
19 | Holy Cross Hospital - Michael and Dianne Bienes Comprehensive Cancer Center | Fort Lauderdale | Florida | United States | 33308 |
20 | Mayo Clinic Florida | Jacksonville | Florida | United States | 32224 |
21 | Mount Sinai Comprehensive Cancer Center | Miami Beach | Florida | United States | 33140 |
22 | Mount Sinai Medical Center | Miami Beach | Florida | United States | 33140 |
23 | Sylvester Comprehensive Cancer Center | Miami | Florida | United States | 33136 |
24 | Baptist Hospital of Miami | Miami | Florida | United States | 33176 |
25 | Miami Cancer Institute | Miami | Florida | United States | 33176 |
26 | Orlando Health Cancer Institute | Orlando | Florida | United States | 32806 |
27 | Orlando Health, Inc. | Orlando | Florida | United States | 32806 |
28 | Orlando Health, Inc | Orlando | Florida | United States | 32806 |
29 | BRCR Medical Center Inc. | Plantation | Florida | United States | 33322 |
30 | Lewis Cancer & Research Pavilion at St Joseph's/Candler Health System | Savannah | Georgia | United States | 31405 |
31 | Lewis Cancer & Research Pavilion Pharmacy | Savannah | Georgia | United States | 31405 |
32 | St. Joseph's/Candler Health System, Inc. | Savannah | Georgia | United States | 31405 |
33 | Summit Cancer Care, P.C. | Savannah | Georgia | United States | 31405 |
34 | Summit Cancer Care | Savannah | Georgia | United States | 31405 |
35 | St. Joseph's/Candler Health System, Inc. | Savannah | Georgia | United States | 31419 |
36 | UChicago Medicine - River East | Chicago | Illinois | United States | 60611 |
37 | The University of Chicago Medical Center, CCD - Investigational Drug Service Pharmacy | Chicago | Illinois | United States | 60637 |
38 | University of Chicago Medical Center | Chicago | Illinois | United States | 60637 |
39 | UChicago Medicine at Ingalls - Flossmoor | Flossmoor | Illinois | United States | 60422 |
40 | UChicago Medicine Ingalls Memorial | Harvey | Illinois | United States | 60426 |
41 | University of Chicago Comprehensive Cancer Center at Silver Cross Hospital | New Lenox | Illinois | United States | 60451 |
42 | The University of Chicago Medicine Center for Advanced Care Orland Park | Orland Park | Illinois | United States | 60462 |
43 | UChicago Medicine at Ingalls - Tinley Park | Tinley Park | Illinois | United States | 60477 |
44 | Ochsner Clinic Foundation Research Pharmacy | New Orleans | Louisiana | United States | 70121 |
45 | Ochsner Clinic Foundation | New Orleans | Louisiana | United States | 70121 |
46 | University of Michigan Hospitals | Ann Arbor | Michigan | United States | 48109 |
47 | University of Michigan | Ann Arbor | Michigan | United States | 48109 |
48 | Mayo Clinic Rochester | Rochester | Minnesota | United States | 55905 |
49 | Mayo Clinic | Rochester | Minnesota | United States | 55905 |
50 | Siteman Cancer Center - West County | Creve Coeur | Missouri | United States | 63141 |
51 | Siteman Cancer Center - North County | Florissant | Missouri | United States | 63031 |
52 | Barnes- Jewish Hospital | Saint Louis | Missouri | United States | 63110 |
53 | Washington University School of Medicine | Saint Louis | Missouri | United States | 63110 |
54 | Siteman Cancer Center - South County | Saint Louis | Missouri | United States | 63129 |
55 | Siteman Cancer Center - St Peters | Saint Peters | Missouri | United States | 63376 |
56 | St Vincent Healthcare | Billings | Montana | United States | 59101 |
57 | St. Vincent Frontier Cancer Center | Billings | Montana | United States | 59102 |
58 | Oncology Hematology West PC dba Nebraska Cancer Specialists | Omaha | Nebraska | United States | 68114 |
59 | Oncology Hematology West PC dba Nebraska Cancer Specialists | Omaha | Nebraska | United States | 68124 |
60 | Oncology Hematology West PC dba Nebraska Cancer Specialists | Omaha | Nebraska | United States | 68130 |
61 | Oncology Hematology West, PC dba Nebraska Cancer Specialists - IP Storage | Omaha | Nebraska | United States | 68130 |
62 | Oncology Hematology West PC dba Nebraska Cancer Specialists | Papillion | Nebraska | United States | 68046 |
63 | Memorial Sloan Kettering Cancer Center - Basking Ridge | Basking Ridge | New Jersey | United States | 07920 |
64 | Summit Medical Group | Berkeley Heights | New Jersey | United States | 07922 |
65 | Summit Medical Group | Florham Park | New Jersey | United States | 07932 |
66 | Memorial Sloan Kettering Cancer Center- Monmouth | Middletown | New Jersey | United States | 07748 |
67 | Memorial Sloan Kettering Cancer Center- Bergen | Montvale | New Jersey | United States | 07645 |
68 | North Shore Hematology Oncology Assoc. P.C. DBA NY Cancer and Blood Specialists | Babylon | New York | United States | 11702 |
69 | North Shore Hematology Oncology Assoc. P.C. DBA NY Cancer and Blood Specialists | Bronx | New York | United States | 10469 |
70 | Memorial Sloan Kettering Cancer Center Commack | Commack | New York | United States | 11725 |
71 | Memorial Sloan Kettering Cancer Center - Westchester | Harrison | New York | United States | 10604 |
72 | Memorial Sloan Kettering Cancer Center | New York | New York | United States | 10022 |
73 | North Shore Hematology Oncology Assoc. P.C. DBA NY Cancer and Blood Specialists | New York | New York | United States | 10028 |
74 | Memorial Sloan Kettering Cancer Center - Main Campus | New York | New York | United States | 10065 |
75 | North Shore Hematology Oncology Assoc. P.C. DBA NY Cancer and Blood Specialists | Patchogue | New York | United States | 11772 |
76 | North Shore Hematology Oncology Assoc. P.C. DBA NY Cancer and Blood Specialists | Port Jefferson Station | New York | United States | 11776 |
77 | North Shore Hematology Oncology Assoc. P.C. DBA NY Cancer and Blood Specialists | Riverhead | New York | United States | 11901 |
78 | Memorial Sloan Kettering Cancer Center- Nassau | Uniondale | New York | United States | 11553 |
79 | Carolinas Medical Center | Charlotte | North Carolina | United States | 28203 |
80 | Carolinas Medical Center Investigational Drug Services | Charlotte | North Carolina | United States | 28204 |
81 | Levine Cancer Institute | Charlotte | North Carolina | United States | 28204 |
82 | Atrium Health Mercy | Charlotte | North Carolina | United States | 28207 |
83 | Atrium Health Pineville | Charlotte | North Carolina | United States | 28210 |
84 | Levine Cancer Institute - Southpark | Charlotte | North Carolina | United States | 28211 |
85 | Atrium Health University City | Charlotte | North Carolina | United States | 28262 |
86 | Levine Cancer Institute University City | Charlotte | North Carolina | United States | 28262 |
87 | Atrium Health Cabarrus | Concord | North Carolina | United States | 28025 |
88 | Levine Cancer Institute - Concord | Concord | North Carolina | United States | 28025 |
89 | Atrium Health Union | Monroe | North Carolina | United States | 28112 |
90 | Investigational Drug Service, The Ohio State University Wexner Medical Center | Columbus | Ohio | United States | 43210 |
91 | The Ohio State University James Cancer Hospital and Solove Research Institute | Columbus | Ohio | United States | 43210 |
92 | Stefanie Spielman Comprehensive Breast Cancer | Columbus | Ohio | United States | 43212 |
93 | Martha Morehouse Medical Plaza | Columbus | Ohio | United States | 43221 |
94 | University of Oklahoma Health Sciences Center, OU Health Stephenson Cancer Center | Oklahoma City | Oklahoma | United States | 73104 |
95 | Providence Cancer Institute Franz Clinic | Portland | Oregon | United States | 97213 |
96 | Providence Portland Medical Center | Portland | Oregon | United States | 97213 |
97 | Providence Onc and Heme Care Clinic - Westside | Portland | Oregon | United States | 97225 |
98 | Providence Oncology and Hematology Care Clinic - Westside | Portland | Oregon | United States | 97225 |
99 | Providence St Vincent Medical Center | Portland | Oregon | United States | 97225 |
100 | Providence St. Vincent Medical Center | Portland | Oregon | United States | 97225 |
101 | AHN Cancer Institute at Jefferson Hospital | Jefferson Hills | Pennsylvania | United States | 15025 |
102 | AHN Cancer Institute Forbes Hospital | Monroeville | Pennsylvania | United States | 15146 |
103 | AHN Cancer Institute - Allegheny General Hospital | Pittsburgh | Pennsylvania | United States | 15212 |
104 | AHN Cancer Institute Pharmacy | Pittsburgh | Pennsylvania | United States | 15212 |
105 | AHN Cancer Institute West Penn Hospital | Pittsburgh | Pennsylvania | United States | 15224 |
106 | UPMC Hillman Cancer Center Investigational Drug Service | Pittsburgh | Pennsylvania | United States | 15232 |
107 | UPMC Hillman Cancer Center | Pittsburgh | Pennsylvania | United States | 15232 |
108 | Wexford Health and Wellness Pavilion | Wexford | Pennsylvania | United States | 15090 |
109 | Vanderbilt Health Clinic at Walgreens Clarksville | Clarksville | Tennessee | United States | 37043 |
110 | Vanderbilt Health Clinic at Walgreens Cool Springs | Franklin | Tennessee | United States | 37067 |
111 | Vanderbilt Health Clinic at Walgreens Gallatin | Gallatin | Tennessee | United States | 37066 |
112 | The West Clinic. PLLC. dba West Cancer Center | Germantown | Tennessee | United States | 38138 |
113 | Vanderbilt Health Clinic at Walgreens Hendersonville | Hendersonville | Tennessee | United States | 37075 |
114 | Vanderbilt Health Clinic at Walgreens Hermitage | Hermitage | Tennessee | United States | 37076 |
115 | Vanderbilt Health Clinic at Walgreens La Vergne | La Vergne | Tennessee | United States | 37086 |
116 | Vanderbilt Health Clinic at Walgreens Lebanon | Lebanon | Tennessee | United States | 37087 |
117 | The West Clinic PLLC dba West Cancer Center | Memphis | Tennessee | United States | 38104 |
118 | Vanderbilt Health Clinic at Walgreens Murfreesboro | Murfreesboro | Tennessee | United States | 37128 |
119 | Vanderbilt Health Clinic at Walgreens Belle Meade | Nashville | Tennessee | United States | 37205 |
120 | Vanderbilt Health Clinic at Walgreens Nippers Corner | Nashville | Tennessee | United States | 37211 |
121 | Vanderbilt Health Clinic at Walgreens Donelson | Nashville | Tennessee | United States | 37214 |
122 | Vanderbilt Health Clinic at Walgreens Hart Lane | Nashville | Tennessee | United States | 37216 |
123 | Vanderbilt Health Clinic at Walgreens Bellevue | Nashville | Tennessee | United States | 37221 |
124 | Vanderbilt-Ingram Cancer Center | Nashville | Tennessee | United States | 37232-6307 |
125 | Henry-Joyce Cancer Center | Nashville | Tennessee | United States | 37232 |
126 | Vanderbilt Oncology IDS Pharmacy | Nashville | Tennessee | United States | 37232 |
127 | Vanderbilt Health Clinic at Walgreens Smyrna | Smyrna | Tennessee | United States | 37167 |
128 | The University of Texas MD Anderson Cancer Center | Houston | Texas | United States | 77030-4009 |
129 | The University of Texas MD Anderson Cancer Center | Houston | Texas | United States | 77030 |
130 | VCU Health System, Investigational Drug Service Pharmacy | Richmond | Virginia | United States | 23298 |
131 | Virginia Commonwealth University Massey Cancer Center | Richmond | Virginia | United States | 23298 |
132 | Seattle Cancer Care Alliance | Seattle | Washington | United States | 98109 |
133 | University of Washington Medical Center | Seattle | Washington | United States | 98195 |
134 | University of Wisconsin Clinical Science Center | Madison | Wisconsin | United States | 53792 |
135 | Froedtert Hospital and the Medical College of Wisconsin | Milwaukee | Wisconsin | United States | 53226 |
136 | Centro Medico San Roque | San Miguel De Tucumán | Tucumán | Argentina | 4000 |
137 | Centro Medico San Roque | Tucuman | Tucumán | Argentina | 4000 |
138 | Instituto Médico Especializado Alexander Fleming | Ciudad Autónoma de Buenos Aires | Argentina | 1426 | |
139 | Clinica Universitaria Reina Fabiola | Cordoba | Argentina | X5004FHP | |
140 | Hospital Privado Centro Médico de Córdoba | Cordoba | Argentina | X5016KEH | |
141 | Hospital Privado Centro Médico de Córdoba | Córdoba | Argentina | X5016KEH | |
142 | Liverpool Hospital | Liverpool | New South Wales | Australia | 2170 |
143 | Slade Pharmacy | Mount Kuring-Gai | New South Wales | Australia | 2080 |
144 | Chris O'Brien Lifehouse | Newtown | New South Wales | Australia | 2042 |
145 | GenesisCare - North Shore | St Leonards | New South Wales | Australia | 2065 |
146 | Northern Cancer Institute | St Leonards | New South Wales | Australia | 2065 |
147 | Royal Brisbane & Women's Hospital | Herston | Queensland | Australia | 4029 |
148 | Princess Alexandra Hospital | Woolloongabba | Queensland | Australia | 4102 |
149 | The Queen Elizabeth Hospital | Adelaide | South Australia | Australia | 5011 |
150 | Monash Health | Clayton | Victoria | Australia | 3168 |
151 | Austin Health | Heidelberg | Victoria | Australia | 3084 |
152 | Peter MacCallum Cancer Centre | Melbourne | Victoria | Australia | 3000 |
153 | Alfred Health | Melbourne | Victoria | Australia | 3004 |
154 | The Alfred Hospital | Melbourne | Victoria | Australia | 3004 |
155 | Université Libre de Bruxelles - Hôpital Erasme | Brussels | Bruxelles-capitale, Région DE | Belgium | 1070 |
156 | Cliniques universitaires Saint-Luc | Brussels | Bruxelles-capitale, Région DE | Belgium | 1200 |
157 | Grand Hôpital de Charleroi | Charleroi | Hainaut | Belgium | 6000 |
158 | CHR Verviers East Belgium | Verviers | Liège | Belgium | 4800 |
159 | AZ Groeninge Campus Kennedylaan | Kortrijk | West-vlaanderen | Belgium | 8500 |
160 | ZNA Middelheim | Antwerpen | Belgium | 2020 | |
161 | UZ Leuven | Leuven | Belgium | 3000 | |
162 | Centre Hospitalier Universitaire de Liège - Domaine Universitaire du Sart Tilman | Liège | Belgium | 4000 | |
163 | Hospital Bruno Born | Lajeado | RIO Grande DO SUL | Brazil | 95900-000 |
164 | Hospital Bruno Born | Lajeado | RIO Grande DO SUL | Brazil | 95900-010 |
165 | Hospital de Clinicas de Porto Alegre | Porto Alegre | RIO Grande DO SUL | Brazil | 90035-903 |
166 | INCA | Rio de Janeiro | RJ | Brazil | 20230-130 |
167 | Instituto Nacional de Câncer José Alencar Gomes da Silva - INCA | Rio de Janeiro | RJ | Brazil | 20230-130 |
168 | Clinica de Oncologia Reichow | Blumenau | Santa Catarina | Brazil | 89010-340 |
169 | Clínica de Neoplasias Litoral | Itajaí | Santa Catarina | Brazil | 88301-220 |
170 | CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia - Faculdade de Medicina do ABC | Santo Andre | SP | Brazil | 09060-650 |
171 | Fundacao do ABC-Faculdade de Medicina do ABC | Santo Andre | SP | Brazil | 09060-870 |
172 | CEPHO - Centro de Estudos e Pesquisas de Hematologia e Oncologia - Faculdade de Medicina do ABC | Santo André | SP | Brazil | 09060-650 |
173 | Fundação Pio XII - Hospital de Câncer de Barretos | Barretos | SÃO Paulo | Brazil | 14784400 |
174 | Medical School Famerp-HB-FUNFARME_Do not use - Duplicate facility | Sao jose do Rio Preto | SÃO Paulo | Brazil | 15090-000 |
175 | Fundação Faculdade Regional de Medicina de São José do Rio Preto | São José do Rio Preto | SÃO Paulo | Brazil | 15090000 |
176 | MHAT Uni Hospital OOD | Panagyurishte | Pazardzhik | Bulgaria | 4500 |
177 | MHAT "Dr. Tota Venkova" AD | Gabrovo | Bulgaria | 5300 | |
178 | Complex Oncology Center - Plovdiv EOOD | Plovdiv | Bulgaria | 4000 | |
179 | MHAT Central Onco Hospital OOD | Plovdiv | Bulgaria | 4000 | |
180 | Medical Center Nadezhda Clinical EOOD | Sofia | Bulgaria | 1303 | |
181 | Acibadem City Clinic MHAT Tokuda | Sofia | Bulgaria | 1407 | |
182 | University Multiprofile Hospital for Active Treatment Sofiamed | Sofia | Bulgaria | 1750 | |
183 | Tom Baker Cancer Centre | Calgary | Alberta | Canada | T2N 4N2 |
184 | Cross Cancer Institute | Edmonton | Alberta | Canada | T6G 1Z2 |
185 | Kingston Health Sciences Centre-Kingston General Hospital Site | Kingston | Ontario | Canada | K7L 2V7 |
186 | London Regional Cancer Program, London Health Sciences Centre | London | Ontario | Canada | N6A 5W9 |
187 | Sunnybrook Health Sciences Centre | Toronto | Ontario | Canada | M4N 3M5 |
188 | Centre Intégré de Santé et de Services Sociaux (CISSS) de Laval / Hôpital de la Cité-de-la-Sant | Laval | Quebec | Canada | H7M 3L9 |
189 | Jewish General Hospital | Montreal | Quebec | Canada | H3T 1E2 |
190 | Anhui Provincial Cancer Hospital | Hefei | Anhui | China | 230031 |
191 | Cancer Hospital Chinese Academy of Medical Science | Beijing | Beijing | China | 100021 |
192 | Beijing Cancer hospital | Beijing | Beijing | China | 100142 |
193 | Beijing Hospital | Beijing | Beijing | China | 100730 |
194 | Fujian Medical University Union Hospital-1 Bingfanglou | Fuzhou | Fujian | China | 350001 |
195 | Affiliated Tumor Hospital of Guangxi Medical University | Nanning | Guangxi | China | 530021 |
196 | Henan provincial people's hospital | Zhengzhou | Henan | China | 450003 |
197 | The Second Xiangya Hospital of Central South University | Changsha | Hunan | China | 410011 |
198 | The Third Xiangya Hospital of Central South University | Changsha | Hunan | China | 410013 |
199 | Nanjing Drum Tower Hospital The Affiliated Hospital of Nanjing University Medical School | Nanjing | Jiangsu | China | 210008 |
200 | Shengjing Hospital Of China Medical University | Shenyang | Liaoning | China | 110022 |
201 | Jinan Central Hospital | Jinan | Shandong | China | 250013 |
202 | The Affiliated Hospital of Qingdao University | Qingdao | Shandong | China | 266031 |
203 | Shanghai Jiaotong University School of Medicine Ruijin Hospital | Shanghai | Shanghai | China | 200025 |
204 | Shanghai General Hospital | Shanghai | Shanghai | China | 200080 |
205 | Sichuan Province Cancer Hospital | Chengdu | Sichuan | China | 610041 |
206 | Yunnan Cancer Hospital(The Third Affiliated Hospital of Kunming Medical University) | Kunming | Yunnan | China | 650118 |
207 | The second Affiliated Hospital of College of Medicine, Zhejiang University | Hangzhou | Zhejiang | China | 310000 |
208 | Peking University First Hospital | Beijing | China | 100034 | |
209 | Fudan University Shanghai Cancer Center | Shanghai | China | 201321 | |
210 | Fakultní nemocnice Brno Bohunice | Brno | Brno-město | Czechia | 625 00 |
211 | Fakultni nemocnice Hradec Kralove | Hradec Kralove | Hradec Králové | Czechia | 500 05 |
212 | Fakultni Thomayerova nemocnice | Prague | Praha 4 | Czechia | 14059 |
213 | Fakultni nemocnice Olomouc | Olomouc | Czechia | 779 00 | |
214 | Fakultni nemocnice v Motole | Praha 5 | Czechia | 150 06 | |
215 | Fakultni nemocnice Bulovka | Praha 8 | Czechia | 180 81 | |
216 | Aalborg Universitetshospital, Syd | Aalborg | Nordjylland | Denmark | 9000 |
217 | Vejle Hospital-Sygehus Lillebaelt | Vejle | Syddanmark | Denmark | 7100 |
218 | Vejle Sygehus | Vejle | Syddanmark | Denmark | 7100 |
219 | Aalborg Universitetshospital | Aalborg | Denmark | 9000 | |
220 | Rigshospitalet | Copenhagen | Denmark | 2100 | |
221 | Herlev Hospital | Herlev | Denmark | 2730 | |
222 | Odense University Hospital | Odense C | Denmark | 5000 | |
223 | Docrates Syöpäsairaala | Helsinki | Nyland | Finland | 00180 |
224 | Tampereen yliopistollinen sairaala | Tampere | Pirkanmaa | Finland | 33520 |
225 | Helsinki University Central Hospital | Helsinki | Finland | 00029 | |
226 | Oulu University Hospital | Oulu | Finland | 90220 | |
227 | Satakunnan Keskussairaala | Pori | Finland | 28500 | |
228 | Turku University Hospital | Turku | Finland | 20520 | |
229 | Muenchen Klinik Neuperlach, Klinik fuer Haematologie und Onkologie | Muenchen | Bayern | Germany | 81737 |
230 | Institut für Klinisch Onkologische Forschung | Frankfurt | Hessen | Germany | 60488 |
231 | Medizinische Hochschule Hannover | Hannover | Lower Saxony | Germany | 30625 |
232 | Medizinische Hochschule Hannover | Hannover | Niedersachsen | Germany | 30625 |
233 | Universitätsklinikum Leipzig | Leipzig | Sachsen | Germany | 04103 |
234 | Radiologie Berlin | Berlin - Charlottenburg | Germany | 10719 | |
235 | Onkologische Schwerpunktpraxis Kurfuerstendamm | Berlin | Germany | 10707 | |
236 | Waage Apotheke | Berlin | Germany | 10709 | |
237 | HELIOS Klinikum Berlin Buch GmbH | Berlin | Germany | 13125 | |
238 | Helios Klinikum Berlin-Buch | Berlin | Germany | 13125 | |
239 | Technische Universität Dresden, Medizinische Fakultät Carl Gustav Carus | Dresden | Germany | 01307 | |
240 | Universitätsklinikum Carl Gustav Carus Dresden | Dresden | Germany | 01307 | |
241 | Facharztzentrum Eppendorf | Hamburg | Germany | 20249 | |
242 | ZytoService Deutschland GmbH, Standort-Hamburg-Jenfeld | Hamburg | Germany | 22045 | |
243 | Radiologie im Israelitischen Krankenhaus | Hamburg | Germany | 22297 | |
244 | Klinikum Oldenburg AöR | Oldenburg | Germany | 26133 | |
245 | Klinikum Oldenburg AöR | Oldenburg | Germany | 26135 | |
246 | Rajiv Gandhi Cancer Institute And Research Centre | New Delhi | Delhi | India | 110 085 |
247 | Rajiv Gandhi Cancer Institute And Research Centre | New Delhi | Delhi | India | 110085 |
248 | Tata Memorial Hospital | Mumbai | Maharashtra | India | 400012 |
249 | Deenanath Mangeshkar Hospital & Research Centre | Pune | Maharashtra | India | 411 004 |
250 | Sahyadri Speciality Hospital | Pune | Maharashtra | India | 411 004 |
251 | Bhakti Vedanta Hospital and Research Institute | Thane | Maharashtra | India | 401107 |
252 | R K Birla Cancer Center, SMS Hospital | Jaipur | Rajasthan | India | 302004 |
253 | Sawai Man Singh Medical College Hospital (SMS Hospital) | Jaipur | Rajasthan | India | 302004 |
254 | Azienda Ospedaliera Universitaria di Cagliari - Presidio Policlinico Universitario "D.Casula" | Monserrato (CA) | Cagliari | Italy | 09042 |
255 | IRCCS Casa Sollievo della Sofferenza | San Giovanni Rotondo | Foggia | Italy | 71013 |
256 | ASST Grande Ospedale Metropolitano Niguarda | Milan | Milano | Italy | 20162 |
257 | Fondazione del Piemonte per l'Oncologia - Istituto di Candiolo IRCCS | Candiolo | Torino | Italy | 10060 |
258 | Azienda Ospedaliero Universitaria San Luigi Gonzaga | Orbassano | Torino | Italy | 10043 |
259 | Fondazione Poliambulanza Istituto Ospedaliero | Brescia | Italy | 25124 | |
260 | Istituto Europeo di Oncologia IRCCS | Milano | Italy | 20141 | |
261 | Azienda Ospedaliera Universitaria dell'Università "Luigi Vanvitelli" di Napoli | Napoli | Italy | 80131 | |
262 | IRCCS Istituto Oncologico Veneto (IOV) | Padova | Italy | 35128 | |
263 | Azienda USL - IRCCS di Reggio Emilia - Arcispedale Santa Maria Nuova | Reggio Emilia | Italy | 42123 | |
264 | Chiba cancer center | Chiba-shi | Chiba | Japan | 260-8717 |
265 | National Cancer Center Hospital East | Kashiwa | Chiba | Japan | 277-8577 |
266 | National Hospital Organization Shikoku Cancer Center | Matsuyama | Ehime | Japan | 791-0280 |
267 | Hokkaido University Hospital | Sapporo | Hokkaido | Japan | 060-8648 |
268 | Kanazawa University Hospital | Kanazawa | Ishikawa | Japan | 920-8641 |
269 | St. Marianna University Hospital | Kawasaki | Kanagawa | Japan | 216-8511 |
270 | Kanagawa cancer center | Yokohama | Kanagawa | Japan | 2418515 |
271 | Aichi Cancer Center Hospital | Nagoya | Nagoya, Aichi | Japan | 464-8681 |
272 | Osaka Prefectural Hospital Organization Osaka International Cancer Institute | Osaka-shi | Osaka | Japan | 5418567 |
273 | Kindai University Hospital | Osakasayama | Osaka | Japan | 589-8511 |
274 | Osaka University Hospital | Suita | Osaka | Japan | 565-0871 |
275 | Osaka Medical and Pharmaceutical University Hospital | Takatsuki | Osaka | Japan | 569-8686 |
276 | Saitama Medical University International Medical Center | Hidaka-city | Saitama | Japan | 350-1298 |
277 | Saitama Prefectural Cancer Center | Ina-machi | Saitama | Japan | 362-0806 |
278 | Shizuoka Cancer Center | Nagaizumi | Shizuoka | Japan | 411-8777 |
279 | National Cancer Center Hospital | Chuo-ku | Tokyo | Japan | 104-0045 |
280 | Japanese Foundation for Cancer Research | Koto-ku | Tokyo | Japan | 135-8550 |
281 | National Hospital Organization Kyushu Cancer Center | Fukuoka | Japan | 811-1395 | |
282 | National Hospital Organization - Osaka National Hospital - Institute For Clinical Research | Osaka | Japan | 540-0006 | |
283 | Keio University Hospital | Tokyo | Japan | 1600035 | |
284 | National Cancer Center | Goyang-si | Gyeonggi-do | Korea, Republic of | 10408 |
285 | Kyungpook National University Hospital | Daegu | Taegu-kwangyǒkshi | Korea, Republic of | 41404 |
286 | Dong-A University Hospital | Busan | Korea, Republic of | 49201 | |
287 | Kyungpook National University Chilgok Hospital | Daegu | Korea, Republic of | 41404 | |
288 | Gachon University Gil Medical Center | Incheon | Korea, Republic of | 21565 | |
289 | Chonnam National University Hwasun Hospital Pharmacy | Jeonnam | Korea, Republic of | 58128 | |
290 | Chonnam National University Hwasun Hospital | Jeonnam | Korea, Republic of | 58128 | |
291 | Korea University Anam Hospital | Seoul | Korea, Republic of | 02841 | |
292 | Seoul National University Hospital | Seoul | Korea, Republic of | 03080 | |
293 | Severance Hospital, Yonsei University Health System | Seoul | Korea, Republic of | 03722 | |
294 | Asan Medical Center | Seoul | Korea, Republic of | 05505 | |
295 | Samsung Medical Center | Seoul | Korea, Republic of | 06351 | |
296 | Accelerium, S. de R.L. de C.V. | Monterrey | Nuevo LEON | Mexico | 64000 |
297 | Centro de Investigacion Clinica de Oaxaca | Oaxaca | Mexico | 68020 | |
298 | Maastricht UMC+ | Maastricht | Limburg | Netherlands | 6229 HX |
299 | Catharina Ziekenhuis | Eindhoven | Noord-brabant | Netherlands | 5623 EJ |
300 | Nederlands Kanker Instituut - Antoni van Leeuwenhoek (NKI-AVL) | Amsterdam | Noord-holland | Netherlands | 1066 CX |
301 | Haaglanden Medisch Centrum | Den Haag | Zuid-holland | Netherlands | 2512 VA |
302 | Haaglanden MC - locatie Westeinde | Den Haag | Netherlands | ||
303 | Haaglanden MC - locatie Westeinde | Leidschendam | Netherlands | 2262 BA | |
304 | Maastricht University Medical Center | Maastricht | Netherlands | 6229 HX | |
305 | Universitair Medisch Centrum Utrecht | Utrecht | Netherlands | 3584 CX | |
306 | Tauranga Hospital | Tauranga | BAY OF Plenty | New Zealand | 3112 |
307 | Auckland City Hospital | Auckland | New Zealand | 1023 | |
308 | Haukeland University Hospital | Bergen | Hordaland | Norway | 5021 |
309 | Stavanger Universitetssykehus | Stavanger | Rogaland | Norway | 4011 |
310 | St. Olavs hospital | Trondheim | Sør-trøndelag | Norway | 7030 |
311 | Sørlandet Sykehus Kristiansand | Kristiansand | Vest-agder | Norway | N-4615 |
312 | Oslo universitetssykehus, Radiumhospitalet | Oslo | Norway | 0379 | |
313 | Oslo Universitetssykehus Ullevål | Oslo | Norway | 0450 | |
314 | Przychodnia Lekarska KOMED | Konin | Wielkopolskie | Poland | 62-500 |
315 | Szpital Specjalistyczny Podkarpacki Ósrodek Onkologiczny w Brzozowie | Brzozow | Poland | 36-200 | |
316 | Wojewodzki Szpital Specjalistyczny Nr 4 w Bytomiu Oddzial Onkologii | Bytom | Poland | 41-902 | |
317 | Wojewodzki Szpital Specjalistyczny Nr 4 w Bytomiu Oddzial Onkologii | Bytom | Poland | 41902 | |
318 | COPERNICUS PL sp. z. o. o. Wojewodzkie Centrum Onkologii w Gdansku Ambulatoryjna | Gdansk | Poland | 80-219 | |
319 | COPERNICUS Podmiot Leczniczy Sp. z o.o. Wojewodzkie Centrum Onkologii | Gdansk | Poland | 80-219 | |
320 | Przychodnia Lekarska KOMED | Konin | Poland | 62-500 | |
321 | Regional Specialised Hospital No. 4 in Bytom | Bytom | Śląskie | Poland | 41-902 |
322 | Sbi "City Clinical Hospital №1 | Nalchik | Kabardino-balkarian Republic | Russian Federation | 360003 |
323 | State budget institution of healthcare of Mordovia Republic "Republic Oncology Dispensary" | Saransk | Republic OF Mordovia | Russian Federation | 430032 |
324 | Private Medical Institution "Euromedservice" | Pushkin | Saint-petersburg | Russian Federation | 196603 |
325 | Private Medical Institution "Euromedservice" | Pushkin | Sankt-peterburg | Russian Federation | 196603 |
326 | GBUZ | Chelyabinsk | Russian Federation | 454087 | |
327 | Kaluga Regional Clinical Oncology Center | Kaluga | Russian Federation | 248007 | |
328 | FSAEI HE I.M Sechenov First MSMU MoH Russia (Sechenovskiy University), | Moscow | Russian Federation | 119991 | |
329 | BHI of Omsk Region "Clinical Oncology Dispensary" | Omsk | Russian Federation | 644013 | |
330 | BHI of Omsk Region "Clinical Oncology Dispensary" | Omsk | Russian Federation | 644046 | |
331 | State Budgetary Healthcare Institution "Orenburg Regional Clinical Oncological Dispensary" | Orenburg | Russian Federation | 460021 | |
332 | LLC "EuroCityClinic" | Saint Petersburg | Russian Federation | 197022 | |
333 | LLC "Medicina Severnoy Stolitsy" | Saint-Petersburg | Russian Federation | 191025 | |
334 | LLC "Severo-Zapadny Medical Center" | Saint-Petersburg | Russian Federation | 192007 | |
335 | Private Healthcare Institution "Clinical Hospital "RZD-Medicine" of St. Petersburg | Saint-Petersburg | Russian Federation | 195271 | |
336 | FSBI "Russian Scientific Center For Radiology and Surgical Technologies n.a. Academician A.M. Granov | St. Petersburg | Russian Federation | 197758 | |
337 | SAHI Republican Clinical Oncology Dispensary under the Ministry of Health, Republic of Bashkortostan | Ufa | Russian Federation | 450054 | |
338 | SHI YR Regional Clinical Oncology Hospital | Yaroslavl | Russian Federation | 150040 | |
339 | SHI YR Regional Clinical Oncology Hospital | Yaroslavl | Russian Federation | 150054 | |
340 | SHI YR Regional Clinical Oncology Hospital | Yaroslav | Russian Federation | 150054 | |
341 | Fakultna nemocnica s poliklinikou F. D. Roosevelta Banska Bystrica | Banska Bystrica | Slovakia | 974 01 | |
342 | Onkologicky ustav sv. Alzbety s.r.o. | Bratislava | Slovakia | 812 50 | |
343 | Narodny Onkologicky Ustav | Bratislava | Slovakia | 833 10 | |
344 | Vychodoslovensky onkologicky ustav, a.s. | Kosice | Slovakia | 04191 | |
345 | POKO Poprad s.r.o. | Poprad | Slovakia | 058 01 | |
346 | Cancercare Rondebosch Oncology | Rondebosch | Cape Town | South Africa | 7700 |
347 | Cancercare Langenhoven Drive Oncology Centre | Port Elizabeth | Eastern CAPE | South Africa | 6045 |
348 | Cancercare Langenhoven Drive Oncology Centre | Port Elizabeth | Eastern CAPE | South Africa | 6055 |
349 | Life Groenkloof | Pretoria | Gauteng | South Africa | 0181 |
350 | Cape Town Oncology Trials | Cape Town | Western CAPE | South Africa | 7570 |
351 | GVI Oncology | Cape Town | Western CAPE | South Africa | 7570 |
352 | Mary Potter Oncology Centre | Pretoria | South Africa | 0181 | |
353 | Complejo Hospitalario Universitario Santiago de Compostela | Santiago de Compostela | A Coruña | Spain | 15706 |
354 | Hospital General Universitario de Elche | Elche | Alicante | Spain | 03203 |
355 | ICO L'Hospitalet (Hospital Duran i Reynals) | Hospitalet de Llobregat | Barcelona | Spain | 08908 |
356 | Hospital Universitario Vall d'Hebron | Barcelona | Spain | 08035 | |
357 | Hospital Clinic Barcelona | Barcelona | Spain | 08036 | |
358 | Hospital General Universitario Gregorio Marañon | Madrid | Spain | 28007 | |
359 | Hospital Universitario Ramon Y Cajal | Madrid | Spain | 28034 | |
360 | Hospital Universitario 12 de octubre | Madrid | Spain | 28041 | |
361 | Hospital Universitario Virgen Del Rocio | Sevilla | Spain | 41013 | |
362 | Hospital Clinico Universitario de Valencia | Valencia | Spain | 46010 | |
363 | Hospital General Universitario de Valencia | Valencia | Spain | 46014 | |
364 | Hospital Universitario Miguel Servet | Zaragoza | Spain | 50009 | |
365 | Karolinska Universitetssjukhuset Solna | Solna | Stockholms LÄN [se-01] | Sweden | 171 64 |
366 | Akademiska sjukhuset | Uppsala | Uppsala LÄN [se-03] | Sweden | 751 85 |
367 | Norrlands universitetssjukhus | Umeå | Västerbottens LÄN [se-24] | Sweden | 90185 |
368 | Sahlgrenska Universitetssjukhuset | Göteborg | Västra Götalands LÄN [se14] | Sweden | 413 45 |
369 | Västmanlands Sjukhus Västerås | Västerås | Sweden | 721 89 | |
370 | Kaohsiung Medical University Chung-Ho Memorial Hospital | Kaohsiung | Taiwan | 807 | |
371 | China Medical University Hospital | Taichung | Taiwan | 40447 | |
372 | National Cheng-Kung University Hospital | Tainan | Taiwan | 704 | |
373 | Chi Mei Hospital, Liouying | Tainan | Taiwan | 73657 | |
374 | National Taiwan University Hospital | Taipei | Taiwan | 10002 | |
375 | Taipei Medical University Hospital | Taipei | Taiwan | 11031 | |
376 | Taipei Veterans General Hospital | Taipei | Taiwan | 11217 | |
377 | Chang Gung Medical Foundation-Linkou Branch | Taoyuan | Taiwan | 333 | |
378 | Medical and diagnostic center of MediX-Ray International Group LLC Israeli Oncology Hospital "LISOD" | Pliuty Village | KYIV Region, Obuhovskiy District | Ukraine | 08720 |
379 | Municipal Non-profit Enterprise "City Clinical Hospital #4" of Dnipro City Council | Dnipro | Ukraine | 49102 | |
380 | PRECARPATHIAN NUCLEAR MEDICINE CENTER, Limited Liability Company | Ivano-Frankivsk | Ukraine | 76011 | |
381 | Ivano-Frankivsk National Medical University | Ivano-Frankivsk | Ukraine | 76018 | |
382 | MNPE "Prykarpatski Clinical Oncological Center" of Ivano-Frankivsk Regional Council" | Ivano-Frankivsk | Ukraine | 76018 | |
383 | Municipal non-profit enterprise "City clinical hospital #2 named after O.O.Shalimov" | Kharkiv | Ukraine | 61037 | |
384 | Communal Non-Profit Enterprise "Regional Center of Oncology" | Kharkiv | Ukraine | 61070 | |
385 | Communal enterprise "Kryvyi Rih Oncology Dispensary" of Dnipropetrovsk Regional Council | Kryvyi Rih | Ukraine | 50048 | |
386 | SI "Insitute of Neurosurgery n.a.acad. A.P. | Kyiv | Ukraine | 04050 | |
387 | SI "Insitute of Neurosurgery n.a.acad. A.P. | Kyiv | Ukraine | 04050 | |
388 | Municipal non-profit enterprise of Kyiv regional council "Kyiv regional clinical hospital" | Kyiv | Ukraine | 04107 | |
389 | Municipal non-profit enterprise "Zaporizhzhia Regional Antitumor Center" Zaporizhzhia Regional | Zaporizhzhia | Ukraine | 69040 | |
390 | Freeman Hospital | Newcastle upon Tyne | HIGH Heaton | United Kingdom | NE7 7DN |
391 | Royal Marsden NHS Foundation Trust | Sutton | Surrey | United Kingdom | SM2 5PT |
392 | Heartlands Hospital | Birmingham | United Kingdom | B9 5SS | |
393 | Royal Marsden NHS Foundation Trust | London | United Kingdom | SW3 6JJ | |
394 | Hammersmith Hospital, Imperial College Healthcare NHS Trust | London | United Kingdom | W12 0HS | |
395 | Charing Cross Hospital, Imperial College Healthcare NHS Trust | London | United Kingdom | W6 8RF | |
396 | Churchill Hospital - Oncology | Oxford | United Kingdom | OX3 7LE |
Sponsors and Collaborators
- Pfizer
- Ono Pharmaceutical Co. Ltd
- Merck KGaA, Darmstadt, Germany
Investigators
- Study Director: Pfizer CT.gov Call Center, Pfizer
Study Documents (Full-Text)
None provided.More Information
Additional Information:
- To obtain contact information for a study center near you, click here.
- Breakwater Study on Pfizer Clinical Trials
Publications
None provided.- C4221015
- 2020-001288-99
- BREAKWATER